AGT and cardiac hypertrophy: Several molecular contributors (e.g., angiotensin II, endothelin 1, catecholamines, mTOR signaling, natriuretic peptides, mechanosensors, sarcomeric proteins, epigenetic regulators, noncoding RNAs, cellular metabolic remodeling, and inflammatory signaling pathways) have been implicated in pathological cardiac hypertrophy (1, 5).